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fluorescence. No antibody response is found in the midpicce and head of 
the epididymis and testes tissue. The seminal plasma inhibitors are 
mainly produced in the seminal vesicles. No immunological cross-reac-
tion was observed with the inhibitors present in the epididymis and 
testes. 
The indirect immunofluorescence antibody technique revealed also 
that ejaculated spermatozoa carry seminal inhibitors, probably at the 
outer acrosomal region, that the inhibitors are removed during residence 
(capacitation) in the uterine fluid (6 hr) , and that uterine spermatozoa 
can be recharged with seminal inhibitors. 
The inhibition of i n v i v o fertilization by treatment of capacitated 
spermatozoa by boar seminal inhibitors has been reported.4-6 
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Antitryptic activity in human seminal plasma was first detected by 
Rasmussen and Albrechtson.' Hacndle et a i r described the occurrence of 
acid-stable trypsin inhibitors in testes, epididymis, and seminal vesicles 
as well as in the seminal plasma of many mammals, including man. 
Fink et a l . 3 and Suominen and Niemi 4 showed that the antitryptic 
activity in human seminal plasma is due to two different trypsin inhibi-
tors, the human seminal plasma inhibitors (HUSI) I and II. H U S I - I , a 
trypsin-chymotrypsin inhibitor, and H U S I - I I , a trypsin-acrosin inhibi-
tor, were further characterized in our laboratory. 5 ' 6 ^ -Ant i t ryps in , an 
' J . Rasmussen and O. K . Albrechtson, Fertil. S t e r i l . 11, 264 (1960). 
* H . Haendle, H . Fritz, I. Trautschold, and E . Werle, Hoppe-Seyler's Z . Physiol. 
C h e m . 343, 185 (1965). 
1 E . Fink, E . Jaumann, H . Fritz, H . Ingrisch, and E . Werle, Hoppe-Seyler's Z . 
Physiol. C h e m . 352, 1591 (1971). 
4 J . Suominen and M . Niemi, / . Reprod. F e r t i l . 29, 163 (1972). 
' H . Schiessler, M . Arnhold, and H . Fritz, Proteinase I n h i b i t o r s , P r o c . I n t . Res, 
Conf., 2nd, ( B a y e r Symp. V ) , Grosse Ledder, 1973 p. 147. Springer-Verlag, Berlin 
and New York, 1974. 
' H . Schiessler, M . Arnhold, and H . Tschesche, Abstr. A n n u . M e e t . Soc. Study 
Reprod., 1974, p. 79. 
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acid-unstable glycoprotein, is also present in human seminal plasma.1 
Trypsin inhibitors isolated from human spermatozoa"''6'8"10 show very 
similar characteristics to those of H U S I - I and H U S I - I I . 
Assay Methods 
T r y p s i n I n h i b i t i o n 
P r i n c i p l e . The inhibition of the tryptic hydrolysis of A/"-benzoyl-DL-
argininc p-nitroanilide ( D L - B A P A ) is measured by following the change 
in absorbance at 405 nm. This standard assay for the determination of 
the inhibitory activity has been described by Fritz et a l . 1 1 and also by 
Kasse l l 1 2 in this series. 
However, iV 0-benzoyl-L-arginine p-nitroanilide ( L - B A P A ) is a better 
substrate than D L - B A P A in this test system, 1 3 since the D-isomer is a 
competitive inhibitor of trypsin. L - B A P A has the further advantage of 
greater solubility and a higher turnover number with trypsin. 
C h y m o t r y p s i n I n h i b i t i o n 1 1 
P r i n c i p l e . The inhibition of the chymotrypsin-catalyzed release 
of p-nitroaniline from A T°-succinyl-L-phenylalanine p-nitroanilide 
( S U P H E P A ) is measured by following the change in absorbance at 
405 nm. 
Reagents 
Substrate: 250 mg of S U P H E P A dissolved in 50 ml of buffer 
Buffer: 0.2 M triethanolamine ( T R A ) , p H 7.8, containing 0.02 M 
C a C l 2 
Enzyme: crystalline A""-p-toluenesulfonyl-L-lysyl chloromethyl 
ketone (TLCK)- t rea ted chymotrypsin is dissolved in 0.0025 A r 
H C l at a concentration of 2 mg/10 ml. The solution is stored at 
4°. 
' G . F . B. Schumacher, Proteinase I n h i b i t o r s , P r o c . I n t . Res. C o n j . , 1st, Munich, 1970 
p. 245. de Gruyter, Berlin, 1971. 
" H . Fritz, B. Förg- l ircy , E . Fink, M . Meier, H . Schiessler, and C . Schirren, H o p p e -
Seyler's Z . Physiol. C h e m . 353, 1943 (1972). 
' L . J . D . Zaneveld, B. M . Dragoje, and G . F . B. Schumacher, Science 177, 702 
(1972). 
1 0 F . N . Synor and R. Kuras, Abstr. A n n u . M e e t . Soc. Study Reprod., 1974, p. 108. 
1 1 H . Fritz, I. Trautschold, and E . Werle, i n "Methoden der Enzymatischen Ana-
lyse" ( H . U . Bergmeyer, ed.), 2nd ed., Vol . I, p. 1021. Verlag Chemie, Weinheim, 
1970. 
" B . Kassell, this series Vol . 19, p. 845. 
" H . Naketa and S. Ishi, J. B i o c h e m . 72, 281 (1972). 
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P r o c e d u r e . The mixture of 0.1 ml of the enzyme solution (correspond-
ing to 6.7 fig of chymotrypsin per mill i l i ter) , the inhibitor solution and 
the buffer (final volume 2.0 ml) is preincubatcd for 5 min. Preincubation 
and the kinetic test are performed at a temperature of 25°. The enzymic 
reaction is started by addition of 1.0 ml of the substrate solution to the 
preincubation mixture. The increase in absorption at 405 nm is followed 
for 20 min. The chymotrypsin activity of the inhibitor-free control serves 
as a reference value for the calculation of the inhibitory activity. 
For the determination of very low inhibitor concentrations or kinetic 
data, the following substrates are recommended: W-benzoyl-L-arginine 
ethyl ester ( B A E E ) and A r"-acetyl-L-tyrosinc ethyl ester ( A T E E ) . The 
conditions to be used for the trypsin-catalyzcd hydrolysis of B A E E and 
the chymotrypsin-catalyzed hydrolysis of A T E E are given by Schwert 
and Takcnaka. 1 4 The assay of trypsin or chymotrypsin inhibition with 
these substrates is performed in identical test systems. The trypsin-
inhibition test with B A E E is extensively described by Burck 1 5 in this 
series. 
A c r o s i n I n h i b i t i o n 
P r i n c i p l e . The substrate specificities of acrosin and trypsin are very 
similar. 1 0 Spectrophotometric measurement of the rate of acrosin-cata-
lyzed hydrolysis of B A E E , D L - B A P A , L - B A P A , or A^-bcnzoyl-L-lysine 
p-nitroanilide ( L - B L N A ) is suitable for quantitative determination of 
acrosin. 1 7 Therefore, the acrosin-inhibition assay may be performed using 
test systems employed for trypsin inh ib i t ion . 1 8 - 2 1 However, purified 
acrosin is strongly adsorbed and inactivated on glass surfaces; the use of 
plastic cuvettes is recommended to minimize this effect.22 
" G . W. Schwert and Y . Takenaka, B i o c h i m . Biophys. A c t a 16, 570 (1955). 
" P. J . Burck, this series Vol. 19, p. 907. 
" H . Schiessler, W.-D. Schleuning, and H . Fritz, Hoppe-Seyler's Z . Physiol. C h e m . 
356, 1931 (1975). 
" W . - D . Schleuning and H . Fritz, this volume [27]. 
" H . Fritz, B. Förg-Brcy, E . Fink, H . Schiessler, E . Jaumann, and M . Arnhold, 
Hoppe-Seyler's Z . Physiol. C h e m . 353, 1007 (1972). 
" H . Schiessler, H . Frilz, M . Arnhold, E . Fink, and H . Tschesche, Hoppe-Seyler's 
Z . Physiol. C h e m . 353, 1638 (1972). 
" H . Fritz, B. Förg-Brcy , M . Meier, M . Arnhold, and H . Tschesche, Hoppe-Seyler's 
Z . Physiol. C h e m . 353, 1950 (1972). 
" L . J . D . Zaneveld, G . F . B. Schumacher, H . Fritz, E . Fink, and E . Jaumann, / . 
Reprod. F e r t i l . 32, (1973). 
a E . Fink, H . Schiessler, M . Arnhold, and H . Fritz, Hoppe-Seyler's Z . Physiol. C h e m . 
353, 1633 (1972). 
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D e f i n i t i o n of U n i t s a n d S p e c i f i c A c t i v i t y . One enzyme unit corresponds 
to the hydrolysis of 1 /jmolc of substrate per minute under the given 
conditions. The change in absorbance due to activity A\l™/m\ii = 3.32 
for the substrates B A P A , B L N A , and S U P H E P A and A\l™/mm = 0.385 
for B A E E . One inhibitor unit causes the reduction of the enzyme mt iv i l \ 
by one enzyme unit. The specific activity is expressed in inhibitor units 
per milligram of protein. 
I n h i b i t i o n of L e u k o c y t i c Proteinases 
P r i n c i p l e . Azocascin is digested by neutral proteinases from leuko-
cytes to products that arc soluble in trichloroacetic acid ( T C A ) . The 
activity o f the proteinases is measured by following the increase in ab-
sorbance at 3G6 nm in the T C A solution (due to the split products). In-
hibition is calculated from the difference between the absorbance of the 
inhibitor-containing samples and the control. 
Reagents 
Substrate: 2 g of azocascin dissolved in lOOrnl of warm buffer 
Buffer: 0.1 M N a 2 H P 0 4 , p H 7.65 
Enzyme: Proteinases from human leukocytes. The enzyme prepara-
tion is extracted from leukocytes of maxillopharyngeal abscesses 
according tOç-Hochstrasscr et a l . 2 3 Of the enzyme-containing pow-
der, 75 mg are dissolved in 5 ml of buffer. Insoluble material is 
removed by centrifugation at 4°. In the test system used, 1.12-4.5 
mg of the enzyme preparation caused an increase in absorbance 
A \ i ? from 0.28 X 10' 3 to 1.2 X 1 0 3 per minute. 
Inhibitor solution: About 0.1 mg of inhibitor is dissolved in 1.0 ml 
of buffer. 
T C A : 5 g of T C A are dissolved in 5 ml of distilled water. 
P r o c e d u r e . Constant amounts of the leukocytic enzyme preparation, 
4.5 mg in 0.3 ml buffer, are incubated at 25° for 1 hr with increasing 
amounts of inhibitor in the phosphate buffer, p H 7.65, in a final volume 
of 1 ml. The enzyme reaction is started by addition of 2.0 ml substrate 
solution to each of the preincubation mixtures. After 3 hr reaction time 
at 37°, proteolysis is stopped by addition of 3.0 ml of T C A solution. The 
absorbance of the centrifuged and filtered supernatant is measured at 
366 nm. 
The values obtained were corrected by subtraction of the absorbance 
of a reference blank containing all reagents but incubated for 0 min. 
3 1 K . Hochstrasser, R. Reichert, S. Schwartz, and E . Werle, Hoppe-Seyler's Z . Physiol. 
C h e m . 353, 221 (1972). 
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T A B L E I 
S U M M A R Y O F T H E P U R I F I C A T I O N P R O C E D U R E 
Step and fraction 
Total 
inhibitory 
activity 
(IU) 
Yield 
(%) 
Specific 
activity* 
(IU/mg) 
Sperm plasma, 1 liter 120 (100) 0.00009 
1 SP-Scphadcx C-50 10S 90 0.017 
2 Trypsin cellulose . 92 7 S 1.2 
3 Sephadcx 0-7Ö 82.5 69 
IIUSP-I 38.3 32 1.37 
IIUSI-II 44:2 37 1.3 
4 SP-Sephadex C-2Ö 
HUSI-I 34.5 90" 1.6 
HUSI-II 40 90* 2.22 
"Trypsin inhibition, substrate: A' a-benzoyl-DL-arginine p-nitroanilide. 
1 Referred to the corresponding preparation from step 3. 
e IIUSI, human seminal plasma inhibitor. 
Purification Procedure 
The procedure is summarized in Table I. 
S t a r t i n g M a t e r i a l 
A trypsin inhibitor activity of 150-330 m I U / m l is detectable in 
freshly ejaculated human seminal plasma. 2 1 This corresponds to the in-
hibition of about 0.1-0.3 mg of bovine trypsin. We received most of our 
material from andrology clinics. These ejaculates had been frozen and 
stored up to one year. The inhibitor concentration in several of these 
batches was up to 50% less than in freshly collected ejaculates.2 5 
Degradation of the inhibitors by proteinases of seminal plasma and 
spermatozoa may be responsible of this reduction. The average inhibitor 
concentrations of abnormal ejaculates (oligospermia, azoospermia, 
aspermia, hypocinctic spermatozoa) and normal ejaculates are not sig-
nificantly different. The seminal plasma of such ejaculates is also suit-
able for inhibitor isolation. 
S t o r a g e C o n d i t i o n s 
In order to prevent extensive degradation, it is recommended that 
the spermatozoa be separated from the seminal plasma by centrifugation 
2 1 H . ITacndle, Dissertation, Medical Faculty, University of Munich, 1969. 
2 5 C . Buck, Andrologie 5, 23 (1973). 
852 N A T U R A L L Y O C C U R R I N G P R O T E A S E INHIBITORS [75| 
(600 fir, 20 min, 4°) immediately after liquefaction of the ejaculates. 
Spermatozoa-free plasma should be frozen preferably below —70°. After 
thawing, the inhibitors should be separated from the residual seminal 
fluid without delay. 
Step 1 . C h r o m a t o g r a p h y o n SP-Sephadex C-50 
i 
This step should be performed rapidly and under constant cooling 
(4°) after thawing the frozen ejaculates or seminal plasma. 
Reagents 
Ammonium acetate buffer, 0.05 M , p H 5.4; 15 liters containing 
0.027c (w/v) N a N 3 
SP-Sephadex C-50, 30 g; i.e., 1 liter of resin, swollen and equili-
brated with buffer 
N a C l , 292 g 
P r o c e d u r e . One liter of a frozen ejaculate pool is thawed (4°) and 
ccntrifuged (600 g) for 2 hr at 4°. The supernatant is removed and 
tested for inhibitory activity. The sediment serves for the isolation of 
the inhibitors from spermatozoa and of acrosin. 
The high-molecular-wcight, acid-labile proteins have to be denatured 
by acidification of the seminal plasma before the concentration of the 
acid-stable inhibitors can be estimated. 
Seminal plasma, 0.5 ml, is diluted with the same volume of per-
chloric acid ( 6 % w / v ) . Denatured proteins arc removed by centrifuga-
tion (6000 fir, 15 min, 4 ° ) . The clear supernatant is neutralized by addi-
tion of solid potassium hydrogen carbonate. If solutions of high ionic 
strength arc applied to the preincubation mixture (enzyme plus inhibitor 
plus buffer), inhibitor-free controls of the same ionic strength should 
be employed in order to avoid misleading results. 
The seminal plasma is diluted with the same volume of buffer. The 
mixture is adjusted to p H 5-4 by addition of acetic acid. Thir ty grams 
of SP-Sephadex C-50, equilibrated with the buffer solution, are added 
and the suspension is stirred slowly for 2 hr at 4°. After ccntrifugation 
(600 g , 15 min, 4°) the resin-free supernatant is decanted and the ad-
sorbent is washed three times with 1 liter of buffer solution. The ad-
sorbent is then packed into a 7 X 50 cm column. The column is washed 
with the buffer solution at a rate of 140 ml /hr until the transmission of 
the eluate has dropped to that of the buffer solution. Then, the column is 
developed with a linear sodium ion gradient formed from 2 liters of 
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starting buffer (0.05 M ammonium acetate buffer p H 5.4) and 2 liters 
of the same buffer containing 1 M sodium chloride. 
The inhibitors arc eluted in a single peak between 0.15 M and 0.5 M 
sodium ion concentration. The combined inhibitor fractions are neu-
tralized with 2 A r N a O H and concentrated by evaporation using a rotary 
evaporator (water bath temperature, 30°) . Desalting is performed by 
passing the concentrated inhibitor solution (max. 25 ml) through a 
Sephadex G-25 column (120 X 3.6 cm) equilibrated and developed with 
2% (v/v) acetic acid. The salt-free inhibitor fractions are combined and 
lyophilizcd. Specific activities between 19 and 25 mIU/mg (trypsin in -
hibition; substrate, D L - B A P A ) were estimated for the material thus 
obtained. 
Step 2. 'Affinity C h r o m a t o g r a p h y 2 " ' 2 ' 
Reagents 
A . "Trypsin, polymer bound on CM-Ccl lu lose" purchased from 
E . Merck, Darmstadt (article No. 24,582, capacity 7-10 U/mg) . 
One gram of the trypsin cellulose is equilibrated with buffer 
B . Fine particles arc removed. The trypsin cellulose is poured 
into a cooled (0°) column (1.2 X 10 cm) and washed with buffer 
B until trypsin and other proteins are noionger detectable in the 
eluate. Used trypsin cellulose may be stored in acidic buffer (C) 
at 4° . 
B . Washing buffer: 0.1 M tricthanolamine-HCl, 0.4 M N a C l , p H 
7.8 
C. Acidic buffer: 0.4 M KC1-HC1, p H 1.8 
P r o c e d u r e . The dry material from step 1 is dissolved in 50 ml of 
buffer B . The inhibitor solution is applied to the column, running at a 
flow rate of 16 ml/hr. The effluent is collected until excess inhibitor ap-
pears in the eluate. Then the column is washed with buffer B until the 
effluent is entirely protein free. Dissociation of the inhibitors from the 
trypsin-inhibitor complex, and thus their clution from the column, is 
achieved by applying buffer C. Elution is stopped when the effluent is 
free of inhibitor. After this procedure the trypsin-cellulose column has 
to be rcequilibrated with buffer B . 
Batchwise operation is also possible. The trypsin-cellulose is care-
fully suspended in the inhibitor solution for 1 hr (4° ) . The adsorbent is 
* B. Kasscll, this series Vol . 19, p. 846. 
* H . Fritz, B. Brey, M . Müller, and M . Gebhardt, P r o t e i n a s e I n h i b i t o r s , P r o c . I n t . 
lies. C o n j . 1st, Munich, 1970 p. 28. de Gruyter, Berlin, 1971. 
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then washed 6 times each with 50 ml of buffer B by repeated suspension 
(for 5 min) and centrifugation. Elution of the inhibitors is achieved by 
repeated (6 times) suspension of the adsorbent in 50 ml of buffer C each 
time. The degree of purification and yields arc comparable for boti) 
methods. 
The acidic inhibitor fractions are combined and concentrated by 
ultrafiltration at 4° to a final volume of 10 ml in an Amicon cell 
equipped with an U M - 0 5 membrane. 
Step 3. S e p a r a t i o n of I I U S I - I a n d H U S I - I I by G e l F i l t r a t i o n o n 
Sephadex G-75 
Separation^of the antitryptic activity into two fractions, a trypsin-
chymotrypsin inhibitor, H U S I - I , and a trypsin-acrosin inhibitor, 
H U S I - I I , is achieved byr gel filtration on Sephadex G-75. 
Concentrated inhibitor solution from step 2, 5 ml, is applied to a 
water-cooled (10°) Sephadex G-75 column (128 X 1.8 cm) equilibrated 
and developed with 2c/c (v/v) acetic acid at a flow rate of 16 ml/hr. 
Fractions of 5 ml are collected. After clution of impurities at the void 
volume, the trypsin-inhibiting activity appears separated into two frac-
tions. The first fraction (v/v„ = 1.84) corresponding to H U S I - I is fol-
lowed by the H U S I - I I fraction (v/v„ = 2.23). The inhibitory activity 
should be estimated in f £ach tube between 40 and 80. The contents of the 
tubes containing H U S I - I and H U S I - I I are pooled separately and lyo-
philizcd. Tubes in the overlap region (Nos. 57-61) containing both in-
hibitors have to be rechromatographed in the same system. 
If the column is calibrated with reference proteins, estimation of the 
molecular weights of the inhibitors is possible. 
Step 4- C h r o m a t o g r a p h y o n SP-Sephadex C-25 
Both H U S I - I and H U S I - I I from step 3 are submitted to gradient 
elution chromatography using identical conditions. 
Reagents 
SP-Sephadex C-25 (Pharmacia Fine Chemicals) 
Buffer I : 0.05 M N a 2 H P O „ p H 6.12 
Buffer I I : 0.05 M NaJHPO-4, p H 6.12, 0.4 M N a C l ( N a + = 0.5 M ) 
P r o c e d u r e . H U S I - I or H U S I - I I , 50 mg, is dissolved in 2-3 ml of buf-
fer I. The clear solution is applied to the SP-Sephadex C-25 column 
(120 X 1 cm) equilibrated with buffer I. The column is developed with 
a linear sodium ion gradient formed from 0.8 liter each of buffer I and 
buffer II at a flow rate of 7 ml /h r ; 3 ml fractions are collected. 
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SO 150 200 300 4 0 0 
Tube No. 
F I G . 1. Fractionation of human seminal plasma inhibitor (HUSI) I by gradient 
clution chromatography on SP-Sephadex C-25 HUSI-I separated from HUSI-II by 
gel nitration (step 3) was employed. The column (120 X 1 cm) was equilibrated with 
sodium phosphate buffer (Na* = 0.1 A/) , p H 6.12, and developed with a linear 
sodium ion gradient formed from 0.8 liter each of starting buffer and 0.4 M NaCl . 
Flow rate: 7 ml/hr, 3 ml/fraction. See text, step 4. 
ta 
Chromatography of the inhibitors H U S I - I and H U S I - I I results in the 
separation of eacli inhibitor fraction into 4 multiple forms (cf. Figs. 1 and 
2). The sodium ion concentration, by which the varous inhibitor fractions 
appear in the eluate, as well as the distribution of the inhibitory activity 
among the fractions, are given in Table II . Tubes containing the same 
inhibitor fraction are combined, concentrated by evaporation, and de-
salted by gel filtration on a Sephadex G-25 column (70 X 2 cm) equili-
brated and developed with 2% (v/v) acetic acid. After lyophilization 
of the salt-free inhibitor fractions, each individual form may be sub-
jected to equilibrium chromatography. 
Step 5. F i n a l P u r i f i c a t i o n by E q u i l i b r i u m C h r o m a t o g r a p h y 
The final purification of each individual fraction may be carried out 
by equilibrium chromatography on a SP-Sephadex C-25 column (120 X 
1 cm; flow rate 7 ml /hr ; 3 ml/fraction) equilibrated and developed 
with a phosphate buffer of constant sodium ion concentration. The exact 
concentration used corresponds to that at which the applied inhibitor is 
eluted during the fractionation in step 4 (cf. Table I I ) . Desalting is 
performed as in step 4. 
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400 
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E 200-
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Tube No. 
F I G . 2. Fractionation of human seminal plasma inhibitor (HUSI) II by gradient 
elution chromatography on SP-Sephadex C - 2 5 . HUSI-II obtained by gel filtration 
on Sephadex G - 7 5 (step 3) was employed. The conditions of this chromatographic 
step are identical to those mentioned in Fig. 1. See text, step 4. 
ex 
T A B L E II 
S E P A R A T I O N O F TIIF. M U L T I P L E F O R M S O F H U M A N S E M I N A L P L A S M A INHIBITOR 
(HUSI) I A N D II F R O M S T E P 3 B Y G R A D I E N T E L U T I O N C H R O M A T O G R A P H Y 
ON S P - S E P H A D K X C - 2 5 « 
HUSI-I fraction 
A B C D 
N a + (moles/liter) 0 . 3 0 5 0 . 3 4 0 . 3 8 0 .41 
Inhibitory activity ( %)b 15 30 24 31 
HUSI-II fraction 
A B C D 
N a + (moles/liter) 0 . 2 1 0 . 2 8 0.33.5 0 .365 
Inhibitory activity ( %)' 9 26 24 41 
• The multiple forms A to D of both inhibitors HUSI-I and HUSI-II appear in 
the eluate at sodium ion concentrations shown in the table. Kechromatography 
of each fraction is performed using these same sodium ion concentrations. 
1 Related to the total inhibitory activity cluted. 
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Properties 
S t a b i l i t y . Both inhibitors arc stallie in solutions of p H 2-9 at room 
temperature. Some lyophilized batches of H U S I - I I (step 3) showed a 
reduction of the specific activity after prolonged storage at 4° . 
M o l e c u l a r W e i g h t . Molecular weight values between 11,000 and 
14,500 were found for H U S I - I and 4000 to 6500 for H U S I - I I by gel 
filtration experiments.3 _ r' From the amino acid compositions shown in 
Table III , a molecular weight near 10,500 is calculated for H U S I - I 
fraction C and 6217 for H U S I - I I fraction D . 
A m i n o A c i d C o m p o s i t i o n . Table III shows the amino acid composi-
tions of H U S I - I fraction D and C and H U S I - I I fraction D . Compared 
T A B L E I I I 
A M I N O A C I D C O M P O S I T I O N O F A C I D - S T A B L E P R O T E I N A S E INHIBITORS F R O M 
H U M A N S E M I N A L P L A S M A " 
Amino acid residues/molecule 
IIUSI'-I HUSI-II 
Amino acid 1) C D 
Aspartic acid 8 8 6 
Threonine 4 4 3 
Serine 6 6 4 
Glutamic acid 7 8 3 
Proline 12 12 5 
Glycine 9 9 5 
Alanine 3 3 1 
Half-cysteinc 12 .12 6 
Valine 5 5 1 
Methionine 3 3 1 
Isoleucine 1 1 3 
Leucine 4 5 2 
Tyrosine 2 2 3 
Phenylalanine 2 2 1 
Lysine 12 12 3 
Histidinc 0 1 2 
Arginine •1 4 5 
Tryptophan 0 0 0 
94 97 54 
Molecular weight 10,130 10,510 0,217 
• The molecular weights given were calculated from the amino acid compositions. 
Amino sugars were not detectable. 
1 HUSI , human seminal plasma inhibitor. 
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T A B L E IV 
INHIBITION S P E C I F I C I T Y O F H U M A N S E M I N A L P L A S M A INHIBITOR ( H U S I ) I A N D ' I I 
Proteinases" Substrate" H U S I - I I I U S I - I I 
Trypsin, 
Human, cationic c T A M E + + 
Human, anionic' T A M E - f + i 
Bovine 3"' B A E E , D L - B A P A + + + 
Acrosin, 
H u m a n " » " » 1 B A E E , D L - B A P A - + + 
Boar 5 ' 1 8 D L - B A P A - + + 
Chymotrypsin, bovine3"* A T E E , S U P H E P A + + 
Leukocytic proteinases, Azocascin + + — 
human, neutral' 
Elastasc, 
Human, granulocytic'' Elastine + — 
Porcine, pancreatic Elastine — — 
Chymotrypsin-likc proteinase A T E E , azocascin — — 
from human sperm plasma" 
" Superscript numbers refer to text footnotes. 
' T A M E , V a-toluencsulfonyl-L arginine methyl ester; B A E E , A'"-bcnzoyl-L-
argininc ethyl ester; D L - B A P A , A'a-bcnzoyl-i>L-arginine p-nitroanilidc; A T E E , 
A^-acetyl-L-tyrosinc ethyl ester; S U P H E P A , A'"-succinyl-L-phenylalaninc 
p-nitroanilidc. O 
' C . Figarella, G . A. Negri, and O. Guy, Proteinase I n h i b i t o r s , Proc. I n t . Res. 
C o n } . , 2nd, (Bayer Symp. V ) , Grosse Lcdder, 1973 p. 213. Springer-Verlag, 
Berlin and New York, 1974. 
d K . Ohlsson, personal communications. 
E II. Fritz, M . Arnhold, B. Förg-Brey , L . J . 1). Zaneveld, and G . F . B. Schumacher, 
Hoppe-Seyler's Z . Physiol. Chem. 353, 1651 (1972). 
to H U S I - I fraction D , H U S I - I fraction C contains three additional 
amino acid residues, whereas the compositions of fraction A and B are 
identical with that of fraction D . Both inhibitors contain neither 
tryptophan nor amino sugar residues. 
The amino acid compositions of inhibitors isolated from freshly col-
lected ejaculates may show differences from the compositions given in 
Tabic III . Peptidases present in the ejaculate may cause loss of amino 
acids or peptides by partial proteolytic degradation. 
N - T e r m i n a l Residues. The only N-terminal residue for H U S I - I frac-
tion D found by substractivc Edman degradation-11 was tyrosine followed 
by leucine. 
I n h i b i t i o n S p e c i f i c i t y (cf. Table I V ) . Neither of the two inhibitors 
" M . Percy and B. Buchwald, A n a l . Biochem. 45, 60 (1972). 
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has any effect on the enzyme activity of human plasmin (Deutsche K a b i 
GmbH) and porcine plasmin (Novo Industri A / S ) , porcine pancreatic 
kal l ikre in , 2 9 subtilisin (Serva A G ) , A s p e r g i l l u s o r y z a e proteinases (Röhm 
G m b H ) , and Pronase (Merck A G , Darmstadt). 
R e a c t i v e S i t e . Trypsin inhibition activity of H U S I - I fraction D was 
not diminished by treatment with excess maleic anhydride and 2,3-
butanedione reagent which arc used for the identification of lysine or 
arginine residues in biologically active regions of proteins. 3 0 This indi-
cates that neither a lysine nor an arginine residue is present in the re-
active site of this inhibitor. 
K i n e t i c P r o p e r t i e s . The following dissociation constants ( K t ) for the 
respective complexes were calculated according to Green and Work . 3 1 
I m m u n o l o g y . Antibodies produced by immunization of rabbits with* 
H U S I - I (step 4, fractions A - D ) cross-react with the trypsin-chymo-
trypsin inhibitor obtained from human spermatozoa and with the acid-
stable trypsin-chymotrypsin inhibitor from cervical mucus, 3 2 ' 3 3 but not 
with H U S I - I I fractions A - D . * i 
P o s s i b l e B i o l o g i c a l F u n c t i o n . 3 2 We assume, that the human seminal 
plasma inhibitor H U S I - I belongs to a special class of trypsin-chymo-
trypsin inhibitors including the inhibitors from respiratory tract secre-
tions 2 3- 3 4 and the inhibitor from cervical mucus. 3 3 These inhibitors form 
strong complexes with neutral proteinases from leukocytes and may pro-
tect mucous membranes against the hydrolytic action of these enzymes. 
On the basis of the inhibition properties it may be concluded that 
H U S I - I I , the trypsin-acrosin inhibitor in human seminal plasma, is the 
natural antagonist of the sperm acrosin. 
• H . Fritz, I. Eckert, and E . Werle, Hoppe-Seyler's Z . Physiol. C h e m . 348, 1120 
(1967). 
" H . Fritz, E . Fink, M . Gebhardt, K . Hochstrasser, and E . Werle, Hoppe-Seyler's 
Z . Physiol. C h e m . 350, 933 (1969). 
" N . M . Green and E . Work, B i o c h e m . J. 54, 347 (1953). 
" H . Fritz, H . Schiessler, W.-B. Schill, H . Tschesche, N . Heimburgcr, and O. Wallner 
iti "Proteases and Biological Control" (E . Reich, D . B . Rifkin, E . Shaw, eds.), 
p. 737, Cold Spring Harbor Laboratory, 1975. 
" O . Wallner and H . Fritz, Hoppe-Seyler's Z . Physiol. C h e m . 355, 709 (1974). 
" K . Hochstrasser, R. Reichert, M . Matzner, and E . Werle, Z . K l i n . C h e m . K l i n . 
B i o c h e m . 10, 1 (1972). 
5 X 10"1 0 AT 
4 X IO"» M 
1 X IO"' M 
9 X I O - 1 0 M 
